c6 nbd ceramide Search Results


m kcl  (Avanti Polar)
94
Avanti Polar m kcl
M Kcl, supplied by Avanti Polar, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/c6+nbd+ceramide/C6-NBD+Ceramide/pmc06254338-320-35-46
Average 94 stars, based on 1 article reviews
m kcl - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
nacl  (MedChemExpress)
94
MedChemExpress nacl
Nacl, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/c6+nbd+ceramide/C6+NBD+Ceramide/pmc13133130-376-30-35
Average 94 stars, based on 1 article reviews
nacl - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
anti cx40  (Santa Cruz Biotechnology)
93
Santa Cruz Biotechnology anti cx40
Anti Cx40, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/c6+nbd+ceramide/C-6+NBD+Ceramide/pmc06679370-256-22-24
Average 93 stars, based on 1 article reviews
anti cx40 - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
dioleoyl sn glycero 3 phosphoethanolamine n  (Croda International Plc)
92
Croda International Plc dioleoyl sn glycero 3 phosphoethanolamine n
Dioleoyl Sn Glycero 3 Phosphoethanolamine N, supplied by Croda International Plc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/c6+nbd+ceramide/C6-NBD+Glucosyl+Ceramide/10__1074_slash_jbc__m109__077594-39-9-29
Average 92 stars, based on 1 article reviews
dioleoyl sn glycero 3 phosphoethanolamine n - by Bioz Stars, 2026-09
92/100 stars
  Buy from Supplier
c6 nbd lactosylceramide  (Croda International Plc)
90
Croda International Plc c6 nbd lactosylceramide
C6 Nbd Lactosylceramide, supplied by Croda International Plc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/c6+nbd+ceramide/C6-NBD+Lactosyl+Ceramide/pmc05722210-136-7-14
Average 90 stars, based on 1 article reviews
c6 nbd lactosylceramide - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
nbd c6 ceramide  (Biotium)
93
Biotium nbd c6 ceramide
Nbd C6 Ceramide, supplied by Biotium, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/c6+nbd+ceramide/NBD+C6-ceramide/pm34920667__nn1c09456_si_001-12-4-16
Average 93 stars, based on 1 article reviews
nbd c6 ceramide - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
c6-nbd sphingomyelin  (Matreya LLC)
90
Matreya LLC c6-nbd sphingomyelin
C6 Nbd Sphingomyelin, supplied by Matreya LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/c6+nbd+ceramide/c6+nbd+ceramide/10__1074_slash_jbc__m805402200-55-0-6
Average 90 stars, based on 1 article reviews
c6-nbd sphingomyelin - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
nbd c6-ceramide  (Becton Dickinson)
90
Becton Dickinson nbd c6-ceramide
Measurements of sphingolipids upon treatment with BHBM. (a) Thin-layer chromatography analysis of sphingolipids (see diagram) isolated from untreated or BHBM-treated C. neoformans cells after in vivo labeling with [ 3 H]palmitate ( 3 H-Palm). (b to h) Lipid analysis by LC-MS. (b) C18 hydroxy (Δ8) 9 methyl-glucosylceramide (GlcCer); (c) C18 dihydroceramide (C18 dhCer); (d) sphingosine and dihydrosphingosine (SPHs); (e) sphingosine-1-phosphate and dihydrosphingosine-1-phosphate (SPH-1-P); (f) C18 hydroxyceramide (C18 OH-Cer); (g) C18 hydroxy <t>Δ8-ceramide</t> (C18 OH-Δ8-Cer); and (h) C18 hydroxy Δ8, 9 methyl-ceramide (C18 OH-Δ8, 9Me-Cer). Values that are significantly different are indicated as follows: *, P < 0.05 comparing treated to untreated (no drug). Statistical analysis was performed using analysis of variance (ANOVA) test. Statistical significance is accepted at a P value of <0.05. Data were compiled from three independent experiments.
Nbd C6 Ceramide, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/c6+nbd+ceramide/nbd+c6+ceramide/pmc04479701-371-6-15
Average 90 stars, based on 1 article reviews
nbd c6-ceramide - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
c6-nbd-ceramide  (Federation of European Neuroscience Societies)
90
Federation of European Neuroscience Societies c6-nbd-ceramide
Measurements of sphingolipids upon treatment with BHBM. (a) Thin-layer chromatography analysis of sphingolipids (see diagram) isolated from untreated or BHBM-treated C. neoformans cells after in vivo labeling with [ 3 H]palmitate ( 3 H-Palm). (b to h) Lipid analysis by LC-MS. (b) C18 hydroxy (Δ8) 9 methyl-glucosylceramide (GlcCer); (c) C18 dihydroceramide (C18 dhCer); (d) sphingosine and dihydrosphingosine (SPHs); (e) sphingosine-1-phosphate and dihydrosphingosine-1-phosphate (SPH-1-P); (f) C18 hydroxyceramide (C18 OH-Cer); (g) C18 hydroxy <t>Δ8-ceramide</t> (C18 OH-Δ8-Cer); and (h) C18 hydroxy Δ8, 9 methyl-ceramide (C18 OH-Δ8, 9Me-Cer). Values that are significantly different are indicated as follows: *, P < 0.05 comparing treated to untreated (no drug). Statistical analysis was performed using analysis of variance (ANOVA) test. Statistical significance is accepted at a P value of <0.05. Data were compiled from three independent experiments.
C6 Nbd Ceramide, supplied by Federation of European Neuroscience Societies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/c6+nbd+ceramide/c6+nbd+ceramide/pm10606729-3-11-21
Average 90 stars, based on 1 article reviews
c6-nbd-ceramide - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
nbd c6-ceramide  (SCHOTT)
90
SCHOTT nbd c6-ceramide
Measurements of sphingolipids upon treatment with BHBM. (a) Thin-layer chromatography analysis of sphingolipids (see diagram) isolated from untreated or BHBM-treated C. neoformans cells after in vivo labeling with [ 3 H]palmitate ( 3 H-Palm). (b to h) Lipid analysis by LC-MS. (b) C18 hydroxy (Δ8) 9 methyl-glucosylceramide (GlcCer); (c) C18 dihydroceramide (C18 dhCer); (d) sphingosine and dihydrosphingosine (SPHs); (e) sphingosine-1-phosphate and dihydrosphingosine-1-phosphate (SPH-1-P); (f) C18 hydroxyceramide (C18 OH-Cer); (g) C18 hydroxy <t>Δ8-ceramide</t> (C18 OH-Δ8-Cer); and (h) C18 hydroxy Δ8, 9 methyl-ceramide (C18 OH-Δ8, 9Me-Cer). Values that are significantly different are indicated as follows: *, P < 0.05 comparing treated to untreated (no drug). Statistical analysis was performed using analysis of variance (ANOVA) test. Statistical significance is accepted at a P value of <0.05. Data were compiled from three independent experiments.
Nbd C6 Ceramide, supplied by SCHOTT, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/c6+nbd+ceramide/nbd+c6+ceramide/10__1021_slash_ac2018124-87-9-12
Average 90 stars, based on 1 article reviews
nbd c6-ceramide - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
d-e-c6 nbd-ceramide  (Matreya LLC)
90
Matreya LLC d-e-c6 nbd-ceramide
Measurements of sphingolipids upon treatment with BHBM. (a) Thin-layer chromatography analysis of sphingolipids (see diagram) isolated from untreated or BHBM-treated C. neoformans cells after in vivo labeling with [ 3 H]palmitate ( 3 H-Palm). (b to h) Lipid analysis by LC-MS. (b) C18 hydroxy (Δ8) 9 methyl-glucosylceramide (GlcCer); (c) C18 dihydroceramide (C18 dhCer); (d) sphingosine and dihydrosphingosine (SPHs); (e) sphingosine-1-phosphate and dihydrosphingosine-1-phosphate (SPH-1-P); (f) C18 hydroxyceramide (C18 OH-Cer); (g) C18 hydroxy <t>Δ8-ceramide</t> (C18 OH-Δ8-Cer); and (h) C18 hydroxy Δ8, 9 methyl-ceramide (C18 OH-Δ8, 9Me-Cer). Values that are significantly different are indicated as follows: *, P < 0.05 comparing treated to untreated (no drug). Statistical analysis was performed using analysis of variance (ANOVA) test. Statistical significance is accepted at a P value of <0.05. Data were compiled from three independent experiments.
D E C6 Nbd Ceramide, supplied by Matreya LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/c6+nbd+ceramide/d+e+c6+nbd+ceramide/10__1074_slash_jbc__m304816200-124-11-13
Average 90 stars, based on 1 article reviews
d-e-c6 nbd-ceramide - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
c6-nbd-ceramide n-{6-[(7-nitro-2-1,3-benzoxadiazol-4-yl)amino]hexanoyl}-d-erythro-sphingosine  (ApexBio)
90
ApexBio c6-nbd-ceramide n-{6-[(7-nitro-2-1,3-benzoxadiazol-4-yl)amino]hexanoyl}-d-erythro-sphingosine
Measurements of sphingolipids upon treatment with BHBM. (a) Thin-layer chromatography analysis of sphingolipids (see diagram) isolated from untreated or BHBM-treated C. neoformans cells after in vivo labeling with [ 3 H]palmitate ( 3 H-Palm). (b to h) Lipid analysis by LC-MS. (b) C18 hydroxy (Δ8) 9 methyl-glucosylceramide (GlcCer); (c) C18 dihydroceramide (C18 dhCer); (d) sphingosine and dihydrosphingosine (SPHs); (e) sphingosine-1-phosphate and dihydrosphingosine-1-phosphate (SPH-1-P); (f) C18 hydroxyceramide (C18 OH-Cer); (g) C18 hydroxy <t>Δ8-ceramide</t> (C18 OH-Δ8-Cer); and (h) C18 hydroxy Δ8, 9 methyl-ceramide (C18 OH-Δ8, 9Me-Cer). Values that are significantly different are indicated as follows: *, P < 0.05 comparing treated to untreated (no drug). Statistical analysis was performed using analysis of variance (ANOVA) test. Statistical significance is accepted at a P value of <0.05. Data were compiled from three independent experiments.
C6 Nbd Ceramide N {6 [(7 Nitro 2 1,3 Benzoxadiazol 4 Yl)amino]Hexanoyl} D Erythro Sphingosine, supplied by ApexBio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/c6+nbd+ceramide/c6+nbd+ceramide+n++6+++7+nitro+2+1+3+benzoxadiazol+4+yl+amino+hexanoyl++d+erythro+sphingosine/10__1128_slash_mbio__01467___19-306-30-32
Average 90 stars, based on 1 article reviews
c6-nbd-ceramide n-{6-[(7-nitro-2-1,3-benzoxadiazol-4-yl)amino]hexanoyl}-d-erythro-sphingosine - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


Measurements of sphingolipids upon treatment with BHBM. (a) Thin-layer chromatography analysis of sphingolipids (see diagram) isolated from untreated or BHBM-treated C. neoformans cells after in vivo labeling with [ 3 H]palmitate ( 3 H-Palm). (b to h) Lipid analysis by LC-MS. (b) C18 hydroxy (Δ8) 9 methyl-glucosylceramide (GlcCer); (c) C18 dihydroceramide (C18 dhCer); (d) sphingosine and dihydrosphingosine (SPHs); (e) sphingosine-1-phosphate and dihydrosphingosine-1-phosphate (SPH-1-P); (f) C18 hydroxyceramide (C18 OH-Cer); (g) C18 hydroxy Δ8-ceramide (C18 OH-Δ8-Cer); and (h) C18 hydroxy Δ8, 9 methyl-ceramide (C18 OH-Δ8, 9Me-Cer). Values that are significantly different are indicated as follows: *, P < 0.05 comparing treated to untreated (no drug). Statistical analysis was performed using analysis of variance (ANOVA) test. Statistical significance is accepted at a P value of <0.05. Data were compiled from three independent experiments.

Journal: mBio

Article Title: Identification of a New Class of Antifungals Targeting the Synthesis of Fungal Sphingolipids

doi: 10.1128/mBio.00647-15

Figure Lengend Snippet: Measurements of sphingolipids upon treatment with BHBM. (a) Thin-layer chromatography analysis of sphingolipids (see diagram) isolated from untreated or BHBM-treated C. neoformans cells after in vivo labeling with [ 3 H]palmitate ( 3 H-Palm). (b to h) Lipid analysis by LC-MS. (b) C18 hydroxy (Δ8) 9 methyl-glucosylceramide (GlcCer); (c) C18 dihydroceramide (C18 dhCer); (d) sphingosine and dihydrosphingosine (SPHs); (e) sphingosine-1-phosphate and dihydrosphingosine-1-phosphate (SPH-1-P); (f) C18 hydroxyceramide (C18 OH-Cer); (g) C18 hydroxy Δ8-ceramide (C18 OH-Δ8-Cer); and (h) C18 hydroxy Δ8, 9 methyl-ceramide (C18 OH-Δ8, 9Me-Cer). Values that are significantly different are indicated as follows: *, P < 0.05 comparing treated to untreated (no drug). Statistical analysis was performed using analysis of variance (ANOVA) test. Statistical significance is accepted at a P value of <0.05. Data were compiled from three independent experiments.

Article Snippet: Fluorescence intensity of yeasts labeled with NBD C6-ceramide were compared using a FACScan flow cytometer (BD Biosciences, Franklin Lakes, NJ).

Techniques: Thin Layer Chromatography, Isolation, In Vivo, Labeling, Liquid Chromatography with Mass Spectroscopy

Effect of BHBM on Golgi morphology in C. neoformans and yeast-to-hyphal differentiation in C. albicans . (A) Control or BHBM-treated cells were stained with NBD C6-ceramide (Golgi and Golgi-derived compartments, green fluorescence). DIC, differential interference contrast; NBD-Cer, NBD 6-ceramide. Bars, 5 µm. (B) FACS analysis shows NBD C6-ceramide accumulation in C. neoformans . The gray histogram corresponds to C. neoformans yeast in the absence of NBD C6-ceramide. CT, control (no BHBM treatment). (C) Percentage of yeast and hyphal forms under control conditions and after BHBM treatment. Statistical analysis was performed using analysis of variance (ANOVA) test. Statistical significance is accepted at a P value of <0.05. The images in panels A and B are representative of three separate experiments. The data in panel C were compiled from three independent experiments.

Journal: mBio

Article Title: Identification of a New Class of Antifungals Targeting the Synthesis of Fungal Sphingolipids

doi: 10.1128/mBio.00647-15

Figure Lengend Snippet: Effect of BHBM on Golgi morphology in C. neoformans and yeast-to-hyphal differentiation in C. albicans . (A) Control or BHBM-treated cells were stained with NBD C6-ceramide (Golgi and Golgi-derived compartments, green fluorescence). DIC, differential interference contrast; NBD-Cer, NBD 6-ceramide. Bars, 5 µm. (B) FACS analysis shows NBD C6-ceramide accumulation in C. neoformans . The gray histogram corresponds to C. neoformans yeast in the absence of NBD C6-ceramide. CT, control (no BHBM treatment). (C) Percentage of yeast and hyphal forms under control conditions and after BHBM treatment. Statistical analysis was performed using analysis of variance (ANOVA) test. Statistical significance is accepted at a P value of <0.05. The images in panels A and B are representative of three separate experiments. The data in panel C were compiled from three independent experiments.

Article Snippet: Fluorescence intensity of yeasts labeled with NBD C6-ceramide were compared using a FACScan flow cytometer (BD Biosciences, Franklin Lakes, NJ).

Techniques: Staining, Derivative Assay, Fluorescence